All In Biotech

Drug Trial Radar · NCT01837667

Phase I Study of LB-100 With Docetaxel in Solid Tumors

A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Feb 2013

Primary completion

Sep 2016

Study completion Sep 2016

Sponsor

Sponsor type
Industry
First posted
Apr 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of cancer (chemotherapeutic agents). Docetaxel is a drug that has been approved for the treatment of some types of cancer; one of the trade names for docetaxel is Taxotere®. The study is in 2 parts. Part 1: Patients will receive injections of LB-100. Part 2: Patients will receive injections of LB-100 and docetaxel. This is the first study where LB-100 for Injection will be used in humans.

Conditions

  • Tumors
  • Neoplasms
  • Cancer

Interventions

  • LB-100 for InjectionDrug

    Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.

  • DocetaxelDrug

    Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.Time frame: Starting from date of first dose up to 30 days after last dose.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Mayo Clinic

    Rochester, Minnesota

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.